Skip to main content
. 2021 Feb 10;11:3461. doi: 10.1038/s41598-021-83019-0

Figure 2.

Figure 2

Comparison of the development anti-SARS-CoV-2 RBD and NP antibodies. Peripheral blood was collected from hospitalized COVID-19 and recovered patients. Negative samples were obtained from true SARS-CoV-2 negative patients (i.e., prior to the SARS-CoV-2 pandemic). Plasma was obtained, diluted 1:50, and added to a 96-well plate precoated with SARS-CoV-2 RBD (ac) or NP (df) antigens. IgG (a,d), IgM (b,e), and IgA (c,f) levels are shown. (af) Kinetics of all samples. Data were calculated using GraphPad Prism 8; the dotted line represents the calculated cutoff values (95% and 98% sensitivity) discriminating between positive and negative samples. Statistical analysis was performed using a Nonparametric Kruskal–Wells test for multiple comparisons.